The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2019

Filed:

Sep. 15, 2014
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Nicholas J. Leeper, Stanford, CA (US);

Irving L. Weissman, Stanford, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12Q 1/6883 (2018.01); A61K 31/519 (2006.01); A61K 31/7068 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 31/519 (2013.01); A61K 31/7068 (2013.01); A61K 38/177 (2013.01); A61K 38/1738 (2013.01); A61K 38/1774 (2013.01); C07K 16/2803 (2013.01); C12Q 1/6883 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.


Find Patent Forward Citations

Loading…